Search results
Results From The WOW.Com Content Network
Diabetes medication. Drugs used in diabetes treat diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin, most GLP-1 receptor agonists ( liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic ...
Glucerna is the brand name of a family of tube feeding formula, bottled or canned shakes, and snack bars manufactured by Abbott Laboratories. [1] It was introduced to the public in 1989. [ 2 ] These medical nutritional products are meant for people with diabetes and are promoted for their ability to satisfy hunger without causing rapid ...
This weight gain can be driven by physical inactivity, stress, poor sleep and poor food choices, such as eating too many ultraprocessed foods, as well as medications, experts say. Weight gain by ...
Most antidepressants are very effective at reducing the severity of depression. However, many are associated with an infamous side effect: weight gain. Luckily, some antidepressants are less ...
e. Orlistat (Xenical), the most commonly used medication to treat obesity and sibutramine (Meridia), a medication that was withdrawn due to cardiovascular side effects. Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of ...
Researchers analyzed the weights of more than 183,000 adult antidepressant users six months, a year and two years after they started taking the drugs.
And when a full year had passed, those taking Ozempic had lost an average of 8.3% of their weight, while those taking Mounjaro had shed an average of 15.3%. The researchers who conducted the ...
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. [1] [2] Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.